Tag: Unprecedented 76-week barzolvolimab results in chronic urticaria

Introduction The expanding frontier of clinical trials is driving progress in diverse areas ranging from immunodermatology to hematologic malignancies and mental health. Innovative therapies are offering new solutions for chronic urticaria, acute myeloid leukemia (AML), and post-traumatic stress disorder (PTSD), underlining the versatility and urgency of clinical research. Barzolvolimab Shows Long-Term Benefits in Chronic Urticaria Celldex Therapeutics has reported unprecedented 76-week results for barzolvolimab, its investigational antibody for chronic urticaria. The treatment specifically targets KIT-expressing mast cells, a major driver of inflammation in this condition. Study insights: Long-lasting reduction in itching and hives. Enhanced patient-reported...